|
Re: Exempt Dist.
|
2
|
Zenith Epigenetics
|
Apr 15, 2021 06:32AM
|
|
Re: Exempt Distribution
|
1
|
Zenith Epigenetics
|
Feb 19, 2021 09:10AM
|
|
Re: Exempt Distribution - 2022-04-14
|
1
|
Resverlogix Corp.
|
Apr 19, 2022 09:42AM
|
|
Re: Exempt Distribution - 2022-04-14
|
2
|
Resverlogix Corp.
|
Apr 19, 2022 12:06PM
|
|
Re: Exempt Distribution - 2022-04-14
|
1
|
Resverlogix Corp.
|
Apr 18, 2022 09:35AM
|
|
Re: Exempt Distribution - 2022-04-14
|
2
|
Resverlogix Corp.
|
Apr 18, 2022 10:31AM
|
|
Re: Exempt Distribution - 2022-04-14
|
3
|
Resverlogix Corp.
|
Apr 18, 2022 01:25PM
|
|
Re: Exempt Distribution 45-106F1
|
1
|
Resverlogix Corp.
|
Mar 27, 2020 12:59PM
|
|
Re: Exercise of options Norma Biln
|
1
|
Resverlogix Corp.
|
Jul 29, 2020 02:42PM
|
|
Re: Exposure in Motley Fool....
|
2
|
Resverlogix Corp.
|
Oct 08, 2019 10:20AM
|
|
Re: Exposure in Motley Fool....
|
2
|
Resverlogix Corp.
|
Oct 08, 2019 02:39PM
|
|
Re: Exposure in Motley Fool....
|
2
|
Resverlogix Corp.
|
Oct 08, 2019 03:06PM
|
|
Re: Fair warning to everyone here....
|
1
|
Resverlogix Corp.
|
Jun 24, 2019 10:16PM
|
|
Re: Fair warning to everyone here....
|
3
|
Resverlogix Corp.
|
Jun 24, 2019 10:30PM
|
|
Re: Farewell
|
2
|
Resverlogix Corp.
|
Jun 13, 2020 09:54AM
|
|
Re: Farxiga (SGLT2i) approved for CKD patients with AND without T2D
|
4
|
Resverlogix Corp.
|
May 03, 2021 05:57AM
|
|
Re: Farxiga (SGLT2i) approved for CKD patients with AND without T2D
|
2
|
Resverlogix Corp.
|
May 03, 2021 07:30AM
|
|
Re: Farxiga (SGLT2i) approved for heart failure
|
2
|
Resverlogix Corp.
|
May 06, 2020 10:08AM
|
|
Re: Fauci and Paxlovid
|
3
|
Resverlogix Corp.
|
Jun 30, 2022 07:31AM
|
|
Re: FDA
|
1
|
Resverlogix Corp.
|
Sep 30, 2019 03:03PM
|
